Neuronetics, Inc. (NASDAQ:STIM) CFO Sells $71,131.77 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 17,307 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $4.11, for a total value of $71,131.77. Following the completion of the sale, the chief financial officer now directly owns 454,420 shares of the company’s stock, valued at approximately $1,867,666.20. This trade represents a 3.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The shares were sold at an average price of $3.83, for a total value of $41,536.35.
• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The shares were sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Stock Performance

Shares of NASDAQ:STIM opened at $4.80 on Friday. Neuronetics, Inc. has a 1 year low of $0.52 and a 1 year high of $5.07. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16. The stock’s 50-day moving average is $2.48 and its 200 day moving average is $1.50.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in Neuronetics by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 314,076 shares of the company’s stock valued at $506,000 after purchasing an additional 8,466 shares during the period. David J Yvars Group increased its holdings in Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after purchasing an additional 14,825 shares during the period. Tradewinds LLC. purchased a new position in Neuronetics during the 4th quarter valued at about $32,000. XTX Topco Ltd purchased a new position in Neuronetics during the 4th quarter valued at about $49,000. Finally, GSA Capital Partners LLP increased its holdings in Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock valued at $60,000 after purchasing an additional 30,837 shares during the period. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.